Renal Thrombotic Microangiopathy: A Review
American Journal of Kidney Diseases, ISSN: 0272-6386, Vol: 81, Issue: 5, Page: 591-605
2023
- 43Citations
- 79Captures
- 5Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations43
- Citation Indexes43
- 43
- CrossRef1
- Captures79
- Readers79
- 79
- Mentions5
- Blog Mentions3
- Blog3
- News Mentions2
- News2
Most Recent News
Late-onset renal TMA and tubular injury in cobalamin C disease: a report of three cases and literature review
Abstract Background Mutation of MMACHC gene causes cobalamin C disease (cblC), an inherited metabolic disorder, which presents as combined methylmalonic aciduria (MMA-uria) and hyperhomocysteinaemia in clinical.
Review Description
Thrombotic microangiopathy (TMA), a pathological lesion observed in a wide spectrum of diseases, is triggered by endothelial injury and/or dysfunction. Although TMA lesions are often accompanied by clinical features of microangiopathic hemolytic anemia, thrombocytopenia, and ischemic end-organ injury, renal-limited forms of TMA are not infrequently encountered in clinical practice. The presence of renal-limited manifestations can be diagnostically challenging, often delaying the initiation of targeted therapy. Prompt investigation and empirical treatment of TMA is warranted to reduce associated morbidity and mortality. Major advances have been made with respect to the pathophysiology of primary TMA entities, with the subsequent development of novel diagnostic tools and lifesaving therapies for diseases like thrombotic thrombocytopenic purpura and complement-mediated TMA. This article will review the clinical presentation and pathologic hallmarks of TMA involving the kidney, and the disease-specific mechanisms that contribute to the endothelial injury that characterizes TMA lesions. Diagnostic approach and both empirical and disease-specific treatment strategies will be discussed, along with the potential role for emerging targeted disease-specific therapies.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0272638622010563; http://dx.doi.org/10.1053/j.ajkd.2022.10.014; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85149649489&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/36509342; https://linkinghub.elsevier.com/retrieve/pii/S0272638622010563; https://dx.doi.org/10.1053/j.ajkd.2022.10.014; https://www.ajkd.org/article/S0272-6386(22)01056-3/fulltext?dgcid=raven_jbs_aip_email#.Y5RzkpiHM9U.twitter; http://www.ajkd.org/article/S0272638622010563/abstract; http://www.ajkd.org/article/S0272638622010563/fulltext; http://www.ajkd.org/article/S0272638622010563/pdf; https://www.ajkd.org/article/S0272-6386(22)01056-3/abstract; https://www.ajkd.org/article/S0272-6386(22)01056-3/fulltext#.Y6O1hPvvSmg.twitter; https://www.ajkd.org/article/S0272-6386(22)01056-3/fulltext?rss=yes&utm_source=dlvr.it&utm_medium=twitter; https://www.ajkd.org/article/S0272-6386(22)01056-3/fulltext?rss=yes; https://www.ajkd.org/article/S0272-6386(22)01056-3/fulltext
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know